Lexaria Bioscience vs Rafael Holdings
Rafael Holdings reported revenue of $1 million in fiscal 2026, 1.3 times Lexaria Bioscience's $1 million in fiscal 2025. Lexaria Bioscience's revenue grew 52.0% in its latest year, and Rafael Holdings' fell 4.7%. Lexaria Bioscience had an operating margin of -1683.0%, against -3822.5% at Rafael Holdings. Free cash flow was −$10 million at Lexaria Bioscience and −$30 million at Rafael Holdings. Their fiscal years end in different months (August 31 and July 31), so the periods don't line up exactly.
Side by side
| Lexaria Bioscience | Rafael Holdings | |
|---|---|---|
| Latest fiscal year | FY2025, Aug 31, 2025 | FY2026, Jul 31, 2026 |
| Revenue | $1M | $1M |
| Revenue growth | 52.0% | −4.7% |
| Revenue growth a year, last 5 years | 18.5% | 2.4% |
| Gross margin | 99.6% | — |
| Operating margin | −1,683.0% | −3,822.5% |
| Net margin | −1,686.0% | −3,390.7% |
| Free cash flow | −$10M | −$30M |
| Free cash flow margin | −1,483.9% | −3,431.3% |
| Return on capital | −929.6% | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 45.3% | 74.7% |
| Last close | $4.49 | $0.90 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | 3 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Lexaria BioscienceRafael Holdings
Operating margin
Percent of revenue
Lexaria BioscienceRafael Holdings
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lexaria BioscienceRafael Holdings
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lexaria Bioscience and Rafael Holdings pages.